Embecta (EMBC) Net Income towards Common Stockholders (2020 - 2026)
Embecta's (EMBC) quarterly Net Income towards Common Stockholders came in at -$4.1 million in Q1 2026, down 117.45% year-on-year from $23.5 million in Q1 2025, and down 109.3% quarter-over-quarter from $44.1 million in Q4 2025.
Embecta (EMBC) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Embecta has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$4.1 million for Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$4.1 million, down 117.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $111.9 million (up 111.93% YoY), and the FY2025 annual result was $95.4 million, up 21.84% from the prior year.
- Net Income towards Common Stockholders came in at -$4.1 million for Q1 2026 at Embecta, down from $44.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $79.6 million in Q1 2022 to a low of -$17.2 million in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is $21.8 million (2023), against an average of $25.6 million.
- Across the five-year window, Net Income towards Common Stockholders plunged 117.75% in 2022 and soared 209.52% in 2025, its largest moves.
- Embecta's Net Income towards Common Stockholders stood at $35.2 million in 2022, then sank by 42.9% to $20.1 million in 2023, then decreased by 27.36% to $14.6 million in 2024, then soared by 202.05% to $44.1 million in 2025, then plunged by 109.3% to -$4.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$4.1 million (Q1 2026), $44.1 million (Q4 2025), and $26.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 826.00 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 239.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 398.73 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 135.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 13.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 112.77 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 2.00 Mn |
| 10 | Embecta | 183.23 Mn | -10.17 Mn | 127.80 Mn | -4.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.10 Mn |
| Dec 31, 2025 | 44.10 Mn |
| Sep 30, 2025 | 26.40 Mn |
| Jun 30, 2025 | 45.50 Mn |
| Mar 31, 2025 | 23.50 Mn |
| Sep 30, 2024 | 14.60 Mn |
| Jun 30, 2024 | 14.70 Mn |
| Mar 31, 2024 | 28.90 Mn |
| Dec 31, 2023 | 20.10 Mn |
| Sep 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 15.20 Mn |
| Mar 31, 2023 | 14.00 Mn |
| Dec 31, 2022 | 35.20 Mn |
| Sep 30, 2022 | -17.20 Mn |
| Jun 30, 2022 | 62.40 Mn |
| Mar 31, 2022 | 79.60 Mn |
| Dec 31, 2021 | 98.80 Mn |
| Sep 30, 2021 | 96.90 Mn |
| Jun 30, 2021 | 104.70 Mn |
| Mar 31, 2021 | 107.90 Mn |